151 related articles for article (PubMed ID: 38420195)
1. Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy.
Xing HL; Ma DH; Li J; Xu QY; Ji LK; Zhu QJ; Luo YQ; Guo MH
Front Pharmacol; 2024; 15():1286422. PubMed ID: 38420195
[No Abstract] [Full Text] [Related]
2. Combination of Rituximab and Low-dose Tacrolimus in the Treatment of Refractory Membranous Nephropathy: A Retrospective Cohort Study.
Chen X; Jiao S; Li S; Li J; Li P; Song F; Yan Z
Balkan Med J; 2023 Jul; 40(4):287-293. PubMed ID: 37260416
[TBL] [Abstract][Full Text] [Related]
3. Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.
Zhu F; Chu X; Guo Y; Li Y; Cao C; Wu J; Xu H; Deng X; Li J; Liu X; Yao Y; Zeng R
Am J Transl Res; 2021; 13(7):7622-7631. PubMed ID: 34377239
[TBL] [Abstract][Full Text] [Related]
4. Optimized rituximab regimen versus recommended regimen for idiopathic membranous nephropathy: A single-center retrospective cohort study.
Yan P; Fang X; Ke B
Int Immunopharmacol; 2024 Mar; 130():111718. PubMed ID: 38377859
[TBL] [Abstract][Full Text] [Related]
5. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy].
Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174
[No Abstract] [Full Text] [Related]
6. [A novel approach to rapid induction of remission in primary membranous nephropathy].
Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN
Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838
[TBL] [Abstract][Full Text] [Related]
7. Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients.
Wang B; Zhu Z; Huang F; Huang H; Tu L; Wang Y; Zheng L; Zhou J; Wei X
BMC Nephrol; 2022 Sep; 23(1):306. PubMed ID: 36068486
[TBL] [Abstract][Full Text] [Related]
8. Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A
Ma Q; Li M; Xu G
Clin Exp Med; 2023 Dec; 23(8):5337-5343. PubMed ID: 37688683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study.
Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B
Front Immunol; 2023; 14():1156470. PubMed ID: 37187749
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy.
Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W
Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study on the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A single-centre experience.
Chen P; Mao M; Wang C; Zhang X; Zhao X; Gao Y; Luo Y; Zhou Y
Front Endocrinol (Lausanne); 2023; 14():1044782. PubMed ID: 36875477
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China.
Zeng L; Chen H; Xiang H; Zeng M; Zhou M; Tan C; Liu H; Chen G
Front Pharmacol; 2023; 14():1309930. PubMed ID: 38259264
[No Abstract] [Full Text] [Related]
15. PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study.
Huang Y; Zhou J; Zhou K; Huang B; Xue J; Zhang X; Liu B; Zhang Z; Zhou L; Cai T; Zhang Y; Hu Z; Wang L; Liu X
PeerJ; 2022; 10():e14193. PubMed ID: 36248712
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tacrolimus monotherapy in primary membranous nephropathy.
Zhang YP; Ran L; Guo L; Gou YL; Guo SS; Xu Y; Hua X; Chen H
Open Med (Wars); 2024; 19(1):20240957. PubMed ID: 38841175
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
Fenoglio R; Baldovino S; Sciascia S; De Simone E; Del Vecchio G; Ferro M; Quattrocchio G; Naretto C; Roccatello D
J Nephrol; 2021 Apr; 34(2):565-571. PubMed ID: 32594370
[TBL] [Abstract][Full Text] [Related]
18. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
[TBL] [Abstract][Full Text] [Related]
19. Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.
Moroni G; Depetri F; Del Vecchio L; Gallelli B; Raffiotta F; Giglio E; Brunini F; D'Amico M; Longhi S; Radice A; Messa P; Sinico RA
Nephrol Dial Transplant; 2017 Oct; 32(10):1691-1696. PubMed ID: 27387472
[TBL] [Abstract][Full Text] [Related]
20. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
